Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Appointed director
|
|
APPLIED GENETIC TECHNOLOGIES CORP (AGTC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/01/2022 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa... |
| 11/29/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/23/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/24/2022 |
8-K
| Quarterly results |
| 08/26/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/12/2022 |
8-K
| Quarterly results |
| 07/14/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 05/09/2022 |
8-K
| Quarterly results |
| 03/23/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and between Applied Genetic Technologies Corporation and Cantor Fitzgerald & Co",
"Opinion of Foley Hoag LLP",
"AGTC Announces Proposed Public Offering of Common Stock GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 21, 2022 — Applied Genetic Technologies Corporation , a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus -based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases , today announced that it has commenced an underwritten public offering of its common stock. All of the shares in the proposed offering are being sold by AGTC. In addition, AGTC expects to grant to the underwriter a 30-day option to purchase up to an additional 15% of shares of the common stock sold in the public offering. The offering is subject to market conditions and there can be no assurance as ...",
"AGTC Announces Pricing of Public Offering of Common Stock GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 22, 2022 — Applied Genetic Technologies Corporation , a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus -based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases , today announced the pricing of its previously announced underwritten public offering of 7,500,000 shares of its common stock for gross proceeds of approximately $9.8 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by AGTC. All of the shares are being sold by AGTC. The offering is expected to close on or about March 24, 2022, subje..." |
|
| 03/02/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021 -Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., February 14, 2022 — Applied Genetic Technologies Corporation , a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus -based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases , today announced financial results for the quarter ended December 31, 2021. “We enter 2022 with significant momentum from the recent buildout of our management team, completion and reporting of several milestones, ..." |
|
| 02/08/2022 |
8-K
| Quarterly results |
| 01/11/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/06/2021 |
8-K
| Quarterly results |
| 11/12/2021 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/09/2021 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : November 9, 2021 APPLIED GENETIC TECHNOLOGIES CORPORATION Delaware 001-36370 59-3553710 14193 NW 119 th Terrace Suite 10 Alachua, Florida, 32165 462-2204 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions . ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communicat...",
"AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2021 -Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 9, 2021 — Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare inherited retinal diseases , today announced financial results for the quarter ended September 30, 2021. “We have significant momentum toward achieving multiple clinical and regulatory milestones in the year ahead. We believe that the data we have generated to date in the Phase 1/2 XLRP clinical tria..." |
|
| 10/14/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/23/2021 |
8-K
| Quarterly results |
| 09/08/2021 |
8-K
| Quarterly results |
| 08/18/2021 |
8-K
| Quarterly results |
| 07/30/2021 |
8-K
| Quarterly results |
| 06/24/2021 |
8-K
| Quarterly results |
| 06/21/2021 |
8-K
| Quarterly results |
| 05/17/2021 |
8-K
| Quarterly results |
| 05/06/2021 |
8-K
| Quarterly results |
| 04/26/2021 |
8-K
| Quarterly results |
| 04/02/2021 |
8-K
| Other Events, Financial Statements and Exhibits |
| 02/11/2021 |
8-K
| Quarterly results |
| 02/01/2021 |
8-K
| Quarterly results |
| 01/29/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Underwriting Agreement, by and among Stifel, Nicolaus & Company, Incorporated, Wells Fargo Securities, LLC and MTS Securities, LLC, as representatives of the underwriters named in Exhibit A thereto",
"Form of Common Stock Purchase Warrant",
"Opinion of Foley Hoag LLP",
"AGTC Announces Proposed Public Offering of Common Stock and Warrants GAINESVILLE, Fla., and CAMBRIDGE, Mass., January 27, 2021 — Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, today announced that it is offering to sell shares of its common stock and pre-funded warrants, together with accompanying warrants to purchase shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are being sold by AGTC. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Stifel, Wells Fargo Securities ...",
"AGTC Announces Pricing of Public Offering of Common Stock and Warrants GAINESVILLE, Fla., and CAMBRIDGE, Mass., January 28, 2021 — Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, today announced the pricing of its previously announced underwritten public offering of 16,741,573 shares of its common stock, together with accompanying warrants to purchase 8,370,786 shares of common stock. The common stock will be sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock sold. The combined offering price to the public of each share of common stock and accompanying warrant is $4.45. The gros..." |
|
| 01/27/2021 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
| 12/23/2020 |
8-K
| Investor presentation |
|
|
|